CsA vs MMC for Preventing Pterygium Recurrence

Adjunctive Use of Topical Cyclosporin A Versus Mitomycin C to Prevent Pterygium Recurrence

aimed to compare the efficacy and safety of topical cyclosporin A (CsA) versus mitomycin C (MMC) as adjunctive therapies in preventing pterygium recurrence after surgical excision.

A total of 40 eyes from 40 patients undergoing pterygium surgery were randomized into two groups: Group A received topical cyclosporin A, while Group B was treated with topical mitomycin C. Ocular surface inflammation scores, recurrence rates, patient-reported symptoms, and adverse effects were assessed at baseline and during follow-up at 6 months postoperatively.

Inclusion Criteria:

• Aged 18 years or older.
• Diagnosed with primary pterygium extending at least 1 mm onto the cornea.
• No prior history of pterygium surgery in the affected eye.

Exclusion Criteria:

• History of ocular surface diseases such as dry eye or Sjögren's syndrome.
• Active ocular infection.
• Known hypersensitivity to CsA or MMC.
• Systemic conditions requiring immunosuppressive therapy.